Capricor Therapeutics 1 article

The scientific profile of Capricor Therapeutics combines cell and exosome therapeutics with deramiocel cardiosphere-derived cells, distinguishing the company from noncellular therapeutic developers. A further part of its cellular strategy is Duchenne muscular dystrophy cell therapy, complemented by allogeneic cardiac progenitor-derived cells; anti-inflammatory regenerative cell therapy supplies the disease or manufacturing context for those engineered cells. Specific cell types, genetic modifications and therapeutic products remain distinct tags; the cellular strategy of Capricor Therapeutics also includes engineered exosome platform.